...
首页> 外文期刊>Journal of molecular graphics & modelling >Targeting essential cell wall lipase Rv3802c for potential therapeutics against tuberculosis
【24h】

Targeting essential cell wall lipase Rv3802c for potential therapeutics against tuberculosis

机译:靶向必需的细胞壁脂肪酶Rv3802c潜在的抗结核疗法

获取原文
获取原文并翻译 | 示例

摘要

Cell wall and lipid metabolism plays a vital role in the survival and infection of Mycobacterium tuberculosis. Increase in the incidences of life-threatening multidrug-resistant (MDR) and extreme drug-resistant (XDR) tuberculosis worsens the existing scenario and urge the need of new druggable targets and new drugs. Targeting Rv3802c, an essential cell wall lipase, can open up a new arsenal to fight the dreadful opportunistic pathogen. Our current study highlights the essentiality of Rv3802c. Its 3D structure is predicted for the first time which provides insight in identifying the ligand binding sites. Our analysis showed Rv3802c is highly conserved throughout mycobacterial species with no significant sequence homolog found in human proteome. Virtual screening followed by comparative docking studies of Rv3802c with its closest human structural homolog has been carried out to identify potential inhibitors effective towards mycobacterial proteins. Two diverse molecules from ZINC database, ZINC26726377 and ZINC43866786 have been identified as potential inhibitors effective towards Rv3802c based on the difference in predicted binding free energy of ?3.99 and ?3.28 kcal/mol respectively. Rv3802c is a promising drug target and also a step towards understanding and targeting the pathogen's cell wall and lipid metabolism simultaneously to combat tuberculosis.
机译:细胞壁和脂质代谢在结核分枝杆菌的存活和感染中起着至关重要的作用。威胁生命的耐多药(MDR)和极端耐药(XDR)肺结核的发病率增加,使现有情况恶化,并敦促需要新的可药物治疗目标和新药物。靶向Rv3802c(一种必需的细胞壁脂肪酶)可以打开新的武器库,以对抗可怕的机会病原体。我们当前的研究突出了Rv3802c的必要性。首次预测了其3D结构,这为鉴定配体结合位点提供了见识。我们的分析表明,Rv3802c在所有分枝杆菌物种中高度保守,在人蛋白质组中未发现明显的序列同源物。进行了虚拟筛选,然后进行Rv3802c与人类最接近的人类结构同源物的对接研究,以鉴定对分枝杆菌蛋白有效的潜在抑制剂。根据预测的结合自由能分别为?3.99和?3.28 kcal / mol,根据ZINC数据库中的两种不同分子ZINC26726377和ZINC43866786被鉴定为对Rv3802c有效的潜在抑制剂。 Rv3802c是有前途的药物靶标,也是朝着同时了解和靶向病原体的细胞壁和脂质代谢以对抗结核病迈出的一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号